• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌手术治疗患者的预后病理特征及算法综述。

A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma.

作者信息

Lohse Christine M, Cheville John C

机构信息

Division of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Clin Lab Med. 2005 Jun;25(2):433-64. doi: 10.1016/j.cll.2005.01.013.

DOI:10.1016/j.cll.2005.01.013
PMID:15848745
Abstract

Accurate subtyping of RCC is critically important and should be considered in algorithms that are developed as prognostic tools for the patient and clinician. The TNM classification, already a powerful prognostic factor, will continue to evolve. The authors recommend that each component of the classification be assessed and reported during pathologic examination. This article also highlighted the importance of assigning a nuclear grade that is based on standardized and reproducible criteria that reflect the heterogeneity of nuclear and nucleolar features within RCC. Lastly, it is increasingly evident that coagulative tumor necrosis and sarcomatoid differentiation are compelling prognostic factors, on par with nuclear grade, and should be assessed routinely. To conclude, the complete list of pathologic features that are evaluated as part of the Mayo Clinic Nephrectomy Registry is presented. The features that are reported routinely in clinical practice also are indicated; this can serve as a guide for the reporting of results from the pathologic examination of RCC.

摘要

肾细胞癌(RCC)的准确亚型分类至关重要,在作为患者和临床医生预后工具而开发的算法中应予以考虑。TNM分类已是一个强大的预后因素,还将继续发展。作者建议在病理检查期间对分类的每个组成部分进行评估和报告。本文还强调了根据反映RCC内核和核仁特征异质性的标准化且可重复的标准来确定核分级的重要性。最后,越来越明显的是,凝固性肿瘤坏死和肉瘤样分化与核分级一样,是令人信服的预后因素,应常规进行评估。总之,列出了作为梅奥诊所肾切除术登记处一部分进行评估的完整病理特征清单。还指出了临床实践中常规报告的特征;这可作为RCC病理检查结果报告的指南。

相似文献

1
A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma.肾细胞癌手术治疗患者的预后病理特征及算法综述。
Clin Lab Med. 2005 Jun;25(2):433-64. doi: 10.1016/j.cll.2005.01.013.
2
Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness.组织学凝固性肿瘤坏死作为肾细胞癌侵袭性的预后指标。
Cancer. 2005 Aug 1;104(3):511-20. doi: 10.1002/cncr.21206.
3
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors.肾细胞癌近期推荐的组织学分类和修订的TNM分期系统的预后效用:瑞士588例肿瘤的经验
Cancer. 2000 Aug 1;89(3):604-14.
4
Prognostic factors for renal cell carcinoma with tumor thrombus extension.伴有肿瘤血栓延伸的肾细胞癌的预后因素
J Urol. 2007 Oct;178(4 Pt 1):1189-95; discussion 1195. doi: 10.1016/j.juro.2007.05.134. Epub 2007 Aug 14.
5
Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.嫌色细胞肾细胞癌:肿瘤分级对预后的影响。
Am J Surg Pathol. 2012 Jun;36(6):851-6. doi: 10.1097/PAS.0b013e3182496895.
6
Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences.pT3a期肾细胞癌的肾周和肾窦脂肪浸润:可能的预后差异
BJU Int. 2009 May;103(10):1349-54. doi: 10.1111/j.1464-410X.2008.08236.x. Epub 2008 Dec 8.
7
Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system.现代重新定义pT3期肾细胞癌:关于修订当前TNM原发肿瘤分类系统的提议
Cancer. 2007 Jun 15;109(12):2439-44. doi: 10.1002/cncr.22713.
8
Significance of macroscopic tumor necrosis as a prognostic indicator for renal cell carcinoma.大体肿瘤坏死作为肾细胞癌预后指标的意义。
J Urol. 2006 Oct;176(4 Pt 1):1332-7; discussion 1337-8. doi: 10.1016/j.juro.2006.06.021.
9
Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.肾外肿瘤扩展的位置不影响pT3a期肾细胞癌患者的生存率。
J Urol. 2007 Nov;178(5):1878-82. doi: 10.1016/j.juro.2007.07.011. Epub 2007 Sep 17.
10
Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.肾静脉及下腔静脉受累在肾细胞癌中的预后价值
Eur Urol. 2009 Feb;55(2):452-9. doi: 10.1016/j.eururo.2008.07.053. Epub 2008 Aug 5.

引用本文的文献

1
FORCE dual-energy CT in pathological grading of clear cell renal cell carcinoma.双能量CT在透明细胞肾细胞癌病理分级中的应用
Oncol Lett. 2019 Dec;18(6):6405-6412. doi: 10.3892/ol.2019.11022. Epub 2019 Oct 30.
2
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.多中心、前瞻性 II 期试验:吉西他滨联合阿昔替尼治疗以梭形细胞成分为主的肾细胞癌患者。
Invest New Drugs. 2019 Dec;37(6):1239-1246. doi: 10.1007/s10637-019-00817-0. Epub 2019 Jun 24.
3
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines.
肾移植治疗既往肾癌患者:当前证据与指南的批判性评估。
J Nephrol. 2019 Feb;32(1):57-64. doi: 10.1007/s40620-018-0542-y. Epub 2018 Oct 16.
4
Positive Surgical Margins Increase Risk of Recurrence after Partial Nephrectomy for High Risk Renal Tumors.高风险肾肿瘤行部分肾切除术时,阳性切缘增加肿瘤复发风险。
J Urol. 2016 Aug;196(2):327-34. doi: 10.1016/j.juro.2016.02.075. Epub 2016 Feb 19.
5
Clinicopathological characteristics and cell cycle proteins as potential prognostic factors in myoepithelial carcinoma of salivary glands.涎腺肌上皮癌的临床病理特征及细胞周期蛋白作为潜在预后因素
Virchows Arch. 2016 Mar;468(3):305-12. doi: 10.1007/s00428-015-1889-2. Epub 2015 Dec 28.
6
Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.COX - 1与VEGF免疫组化联合应用可优化肾细胞癌的组织病理学预后。
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8165-77. eCollection 2015.
7
Spontaneous regression of metastatic pulmonary renal cell carcinoma in the setting of sarcomatoid differentiation of the primary tumour.原发性肿瘤呈肉瘤样分化背景下转移性肺肾细胞癌的自发消退。
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):E587-9. doi: 10.5489/cuaj.169.
8
Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.多梳组基因是肾细胞癌中异常 DNA 甲基化的靶标。
Epigenetics. 2011 Jun;6(6):703-9. doi: 10.4161/epi.6.6.16158. Epub 2011 Jun 1.
9
Misdiagnosis of clear cell renal cell carcinoma.误诊为透明细胞肾细胞癌。
Nat Rev Urol. 2011 May 17;8(6):321-33. doi: 10.1038/nrurol.2011.64.
10
Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.伴肉瘤样分化的肾细胞癌中使用替西罗莫司:三例报告。
Med Oncol. 2012 Jun;29(2):795-8. doi: 10.1007/s12032-011-9976-y. Epub 2011 May 11.